ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,631.22
      0.28%
      US Tech 100
      19,858.00
      0.06%
      Dow Jones
      40,211.72
      0.53%
      Brent Oil
      83.615
      -0.86%
      Bitcoin
      63,095.28
      -2.71%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Silverback Therapeutics Inc (SBTX)

      7. Silverback Therapeutics Inc (SBTX) News

      SBTX

      Silverback Therapeutics (SBTX)

      Silverback Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SBTX
      DateTimeSourceHeadlineSymbolCompany
      11/18/20222:18PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
      11/18/20221:59PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:01PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:01PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20225:01PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
      11/10/20228:00AMGlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
      11/08/20224:52PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
      11/08/20224:02PMGlobeNewswire Inc.ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics Inc
      11/02/20224:12PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
      11/02/20226:08AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
      10/27/20224:17PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SBTXSilverback Therapeutics Inc
      10/21/20228:36AMDow Jones NewsSilverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review ApprovalNASDAQ:SBTXSilverback Therapeutics Inc
      10/21/20227:47AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SBTXSilverback Therapeutics Inc
      10/21/20227:36AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
      10/21/20227:31AMBusiness WireSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
      10/06/20224:17PMEdgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:SBTXSilverback Therapeutics Inc
      09/30/20224:08PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
      09/02/20224:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
      08/11/20225:23PMEdgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:SBTXSilverback Therapeutics Inc
      08/11/20224:05PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
      08/09/20224:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:SBTX

      Your Recent History

      NASDAQ
      GWII
      Good Works II Acquisition
      Delayed Upgrade Clock